Phase 3 N=105 Analgesic Effect of Peripheral Dexmedetomidine
Third Molar Extraction
Primary: Pain Score at Rest — 165.5; 218.2; 233.8 score on a scale×hr
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=271 Study of Safety, Tolerability and Immunogenicity of Gardasil®9 in Immunocompromised Patients
Human Papilloma Virus · Hiv · Organ Transplants
Primary: Seroconversion Following 3 Doses of 9-valent HPV Vaccines — 100; 64.2; 100; 70.7 Percentage of participants
Phase 3 N=131 Phase 3b Study of Metvix NDL-PDT Versus Metvix c-PDT in Subjects With Actinic Keratoses
Actinic Keratoses
Primary: Percentage (%) Change From Baseline in Total Lesion Complete Response at Week 12 in Group 1 — 68.4; 71.5 percentage change from baseline — p==0.2665
Phase 3 N=299 Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients
Prostate Cancer
Primary: Sensitivity of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy — .43 proportion of participants
Phase 3 N=104 Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis
Acute Alcoholic Hepatitis
Primary: 180 Days Mortality — 17; 22; 0 Participants — p=.30
Phase 3 N=166 Evaluation of EXPAREL for Prolonged Postsurgical Analgesia in Subjects Undergoing Third Molar Extraction
Dental Pain
Primary: Area Under the Curve (AUC) of Numeric Rating Scale (NRS) Pain Intensity Scores Through 48 Hours — 178.9; 181.6 units on NRS scale*hr — p=0.8661
Phase 3 N=449 Immunogenicity, Reactogenicity and Safety Study of Two Different Formulations of GSK Biologicals' Human Rotavirus Vaccine, Rotarix, in Healthy Infants
Rotavirus
Primary: Anti-rotavirus (Anti-RV) Immunoglobulin A (IgA) Antibody Concentrations — 90.25; 94.16 U/mL
Phase 3 N=483 Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer
Small Cell Lung Cancer
Primary: Overall Survival (OS) — 6.9; 7.0; 7.4 months
Phase 3 N=191 Intercostal Nerve Block With Liposome Bupivacaine in Subjects Undergoing Posterolateral Thoracotomy
Posterolateral Thoracotomy · Postoperative Pain
Primary: Area Under the Curve (AUC) of Pain Intensity at Rest Through 72 Hours — 472.1; 459.0 score on a scale * hr — p=0.5598
Phase 3 N=667 Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face
Rosacea
Primary: Percent Change (Reduction) of Lesion Count From Day 1 — 61.14; 57.27; 49.43 percentage of lesion reduction
Phase 3 N=101 Femoral Nerve Block With Liposome Bupivacaine for Postsurgical Analgesia Following Total Knee Arthroplasty
Postoperative Pain
Primary: Area Under the Curve (AUC) of Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores Through 72 Hours — 533.4; 427.2; 436.2; 530.5 score on a scale * hr — p=0.9494
Phase 3 N=315 This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.
Heart Failure
Primary: Change From Baseline to Week 12 in Exercise Capacity as Measured by the Distance Walked in 6 Minutes in Standardised Conditions (6MWTD) — 5.0; 10.0 Meter (m) — p=0.3660
Phase 3 N=450 Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLC
NSCLC
Primary: Objective Response Rate — 46.4; 44.3 percentage of participants
Phase 3 N=34 Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea
Advanced Cancers
Primary: Modified Dyspnea Borg Scale (Dyspnea Intensity) — -1.4; -0.5 score on a scale
Phase 3 N=6,564 Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
Peripheral Artery Disease
Primary: Primary Efficacy Outcome: Number of Participants With Composite of Myocardial Infarction (MI), Ischemic Stroke, Cardiovascular Death, Acute Limb Ischemia (ALI) and Major…